Annexure-9
Business Responsibility &
Sustainability Report
SECTION A: GENERAL DISCLOSURES
- Details of the listed entity
- Corporate Identity Number (CIN) of the Listed Entity: L74899DL1995PLC065388
- Name of the Listed Entity: Dr. Lal PathLabs Limited
- Year of incorporation: 1995
- Registered office address: Block E, Sector-18, Rohini, New Delhi-110085
- Corporate address: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38,Gurugram-122001
- E-mail: cs@lalpathlabs.com
7. Telephone: 0124-3016500
8 Website: www.lalpathlabs.com
- Financial year for which reporting is being done: FY 2021-22
-
Name of the Stock Exchange(s) where shares are listed: National Stock Exchange of India Limited and
BSE Limited - Paid-upCapital: ` 83,34,48,770 divided into 8,33,44,877 Equity Shares of ` 10/- each
12 Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the BRSR report: Mr. Manoj Garg, Chief Human Resource Officer, Tel: + 91-124-3016-500,
Email: manoj.garg@lalpathlabs.com
- Reporting boundary - Are the disclosures under this report made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements, taken together): Standalone basis
II. Products/services
- Details of business activities (accounting for 90% of the turnover):
S. No. | Description of Main Activity | Description of | % of Turnover of |
Business Activity | the entity | ||
1. | Other Human Health Activities | Activities of Independent | 100% |
Diagnostics/Pathological | |||
Laboratories |
15. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):
S. No. | Product/Service | NIC Code | % of total Turnover |
contributed | |||
1. | Diagnostic and related healthcare | 869 | 100% |
tests and services |
72 Annual Report 2021 - 22
Statutory Reports
III. Operations
16. Number of locations where plants and/or operations/offices of the entity are situated:
Location | Number of plants | Number of | Total |
offices / Labs | |||
National
International
Not Applicable as the Company provides Diagnostic Services in the area of Pathology and Radiology
195195*
22
* Standalone Number | ||||
17. Markets served by the entity: | ||||
a. Number of locations | ||||
Locations | Number | |||
National (No. of States) | The Company has Laboratories in 25 States and | |||
5 Union Territories. | ||||
International (No. of Countries) | India, Nepal and Bangladesh. | |||
Besides the above, the Company also receives samples | ||||
from International Locations like Bhutan, Sri Lanka, | ||||
Myanmar, Malaysia, Cambodia, Maldives, UAE, Saudi | ||||
Arabia, Bahrain, Qatar, Kuwait, Ethiopia, Tanzania, | ||||
Uganda, Malawi, Zambia, Nigeria, Ghana, Sierra Leone | ||||
& Mauritius for testing in India. | ||||
- What is the contribution of exports as a percentage of the total turnover of the entity?
1% (one percent) - A brief on types of customers:
The Company's customers include individual patients, hospitals, other healthcare providers and corporate customers.
IV. Employees
18. Details as at the end of Financial Year:
a. Employees and workers (including differently abled):
S. | Particulars | Total | Male | Female | ||||||
No. | (A) | No. (B) | % (B / A) | No. (C) | % (C / A) | |||||
EMPLOYEES | ||||||||||
1. | Permanent (D) | 1,289 | 1,042 | 80.84 | 247 | 19.16 | ||||
2. | Other than | 120 | 64 | 53.33 | 56 | 46.67 | ||||
Permanent (E) | ||||||||||
3. | Total employees (D + E) | 1,409 | 1,106 | 78.5 | 303 | 21.50 | ||||
WORKERS* | ||||||||||
4. | Permanent (F) | 2,821 | 2,163 | 76.67 | 658 | 23.33 | ||||
5. | Other than | 11 | 5 | 45.45 | 6 | 54.55 | ||||
Permanent (G) | ||||||||||
6. | Total workers (F + G) | 2,832 | 2,168 | 76.55 | 664 | 23.45 | ||||
* Based on an internal assessment, we have categorised employees below a certain grade as Workers.
Note: Workers and Employees includes all people who were on the payrolls of the Company as of March 31, 2022, except 11, who were on Lal PathLabs Foundation payroll.
Dr. Lal PathLabs Limited 73
- Differently abled Employees and workers:
S. | Particulars | Total | Male | Female | ||||||||||||||||||
No | (A) | No. (B) | % (B / A) | No. (C) | % (C / A) | |||||||||||||||||
DIFFERENTLY ABLED EMPLOYEES | ||||||||||||||||||||||
1. | Permanent (D) | - | - | - | - | - | ||||||||||||||||
2. | Other than | - | - | - | - | - | ||||||||||||||||
Permanent (E) | ||||||||||||||||||||||
3. | Total differently abled | - | - | - | - | - | ||||||||||||||||
employees (D + E) | ||||||||||||||||||||||
DIFFERENTLY ABLED WORKERS | ||||||||||||||||||||||
4. | Permanent (F) | 12 | 12 | 100 | - | - | ||||||||||||||||
5. | Other than | - | - | - | - | - | ||||||||||||||||
permanent (G) | ||||||||||||||||||||||
6. | Total differently abled | 12 | 12 | 100 | - | - | ||||||||||||||||
workers (F + G) | ||||||||||||||||||||||
19. Participation/Inclusion/Representation of women | ||||||||||||||||||||||
Total | No. and percentage of Females | |||||||||||||||||||||
(A) | No. (B) | % (B / A) | ||||||||||||||||||||
Board of Directors | 10 | 3 | 30 | |||||||||||||||||||
Key Management Personnel | 6 | 1 | 17 | |||||||||||||||||||
20. Turnover rate for permanent employees and workers | ||||||||||||||||||||||
(Disclose trends for the past 3 years) | ||||||||||||||||||||||
FY 2020-21 | FY 2019-20 | |||||||||||||||||||||
FY 2021-22 | ||||||||||||||||||||||
(Turnover rate in current | (Turnover rate in previous | (Turnover rate in the year | ||||||||||||||||||||
FY) | FY) | prior to the previous FY) | ||||||||||||||||||||
Male | Female | Total | Male | Female | Total | Male | Female | Total | ||||||||||||||
Permanent | 25.17 | 21.69 | 24.53 | 16.90 | 17.05 | 16.93 | 23.23 | 14.62 | 21.82 | |||||||||||||
Employees | ||||||||||||||||||||||
Permanent | 12.49 | 15.56 | 13.21 | 10.95 | 12.56 | 11.33 | 10.97 | 14.61 | 11.84 | |||||||||||||
Workers |
- Holding, Subsidiary and Associate Companies (including joint ventures)
21. (a) Names of holding / subsidiary / associate companies / joint ventures
S. | Name of the holding/ | Indicate whether | % of shares held | Does the entity |
No. | subsidiary/ associate | holding/ | by listed entity | indicated at column |
companies/ joint | Subsidiary/ | A, participate in the | ||
ventures (A) | Associate/ Joint | Business Responsibility | ||
Venture | initiatives of the listed | |||
entity? (Yes/No) | ||||
1 | Paliwal Diagnostics Private | Subsidiary | 80 | No |
Limited | ||||
2 | Paliwal Medicare Private | Subsidiary | 80 | No |
Limited | ||||
3 | APL Institute of Clinical | Subsidiary | 100 | No |
Laboratory & Research Private | ||||
Limited |
74 Annual Report 2021 - 22
Statutory Reports | ||||
S. | Name of the holding/ | Indicate whether | % of shares held | Does the entity |
No. | subsidiary/ associate | holding/ | by listed entity | indicated at column |
companies/ joint | Subsidiary/ | A, participate in the | ||
ventures (A) | Associate/ Joint | Business Responsibility | ||
Venture | initiatives of the listed | |||
entity? (Yes/No) | ||||
4 | Dr. Lal Ventures Private | Subsidiary | 100 | No |
Limited | ||||
5 | PathLabs Unifiers Private | Subsidiary | 100 | No |
Limited | ||||
6 | Centrapath Labs Private | Step down | 70 | No |
Limited | Subsidiary | |||
7 | APRL PathLabs Private | Step down | 70 | No |
Limited | Subsidiary | |||
8 | Chanre Laboratory Private | Step down | 70 | No |
Limited | Subsidiary | |||
9 | Dr. Lal PathLabs Nepal | Subsidiary | 100 | No |
Private Limited | ||||
10 | Dr. Lal Path Labs | Subsidiary | 71.83 | No |
Bangladesh Private Limited | ||||
11 | Dr. Lal PathLabs Kenya | Subsidiary | 100 | No |
Private Limited | ||||
12 | Suburban Diagnostics | Subsidiary | 100 | No |
(India) Private Limited |
VI. CSR Details
22. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes
- Turnover : ` 18,727.06 Millions
- Net worth : ` 16,502.65 Million
Dr. Lal PathLabs Limited 75
22 - 2021 Report Annual 76
VII. Transparency and Disclosures Compliances
23. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:
Stakeholder | Grievance Redressal | FY 2021-22 | FY 2020-21 | |||||||||||||
group from | Mechanism in Place (Yes/No) | Current Financial Year | Previous Financial Year | |||||||||||||
whom | (If Yes, then provide web-link | Number of | Number of | |||||||||||||
complaint is | for grievance redress policy) | Number of | complaints | Remarks | Number of | complaints | Remarks | |||||||||
received | complaints | pending | complaints | pending | ||||||||||||
filed during | resolution at | filed during | resolution at | |||||||||||||
the year | close of the | the year | close of the | |||||||||||||
year | year | |||||||||||||||
Communities | No | There weren't any complaints / grievances received from any specific community. | ||||||||||||||
Investors | Yes. | There were no complaints that were received. | ||||||||||||||
(other | Investors can contact the | |||||||||||||||
than | officials | mentioned in the link | ||||||||||||||
shareholders) | below https://www.lalpathlabs. | |||||||||||||||
com/investor/investor-contact. | ||||||||||||||||
aspx | ||||||||||||||||
Shareholders | Yes | 187 | 5 | 5 (Five) | 438 | - | 6 (Six) | |||||||||
Shareholders, for any of their | Shareholders | Shareholders | ||||||||||||||
grievances can reach out to the | Complaints were | Complaints were | ||||||||||||||
Company Secretary at | unresolved as of | carry forward of | ||||||||||||||
https://www.lalpathlabs.com/ | March 31, 2022. | previous years | ||||||||||||||
Those 5 have | which were also | |||||||||||||||
investor/investor-contact.aspx | ||||||||||||||||
been resolved as | resolved during | |||||||||||||||
of date. | the current year. | |||||||||||||||
Employees | The Company does have a | There weren't any complaints / grievances received. | ||||||||||||||
and workers | specific internal Grievance | |||||||||||||||
Redressal Policy in place. | ||||||||||||||||
Customers* | The Company does not have | 79,274 | 237 | The unresolved | 54,177 | - | ||||||||||
a specific | Grievance Redressal | complaints as of | ||||||||||||||
Policy in place. | March 31, 2022 | |||||||||||||||
However, there is a dedicated | have all been | |||||||||||||||
helpline number (011- | subsequentlly | |||||||||||||||
49885050) and email id | resolved. | |||||||||||||||
customer.care@lalpathlabs. | ||||||||||||||||
com which address and | ||||||||||||||||
resolves all customer | ||||||||||||||||
grievances. | ||||||||||||||||
Value Chain | No | There were no complaints/grievances received from the Value Chain Partners except some | ||||||||||||||
Partners | outstanding dues related clarifications, which were properly addressed and resolved. | |||||||||||||||
Other (please | - | - | - | - | ||||||||||||
specify) | ||||||||||||||||
* The increase in Customer cases from the previous year is majorily attributable to an unparallel rise in Covid-19 cases
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Dr. Lal PathLabs Ltd. published this content on 09 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 June 2022 05:41:03 UTC.